Literature DB >> 16107836

Prospects for a vaccine against the hepatitis C virus.

Michael Houghton1, Sergio Abrignani.   

Abstract

The recent discovery of natural immunity to the hepatitis C virus and vaccine efficacy in the chimpanzee challenge model has allowed optimism about the development of at least a partly effective vaccine against this heterogeneous pathogen that is responsible for much of the chronic liver disease around the world. The immune systems of some infected individuals can spontaneously clear the virus, whereas other people need treatment with antivirals that work partly by stimulating humoral and cellular immune responses. Therefore, therapeutic vaccine strategies are also being pursued to improve treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107836     DOI: 10.1038/nature04081

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  100 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

Review 2.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

5.  Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.

Authors:  Shuanghu Liu; Cassie A Nelson; Li Xiao; Ling Lu; Punit P Seth; Darrell R Davis; Curt H Hagedorn
Journal:  Antiviral Res       Date:  2010-11-12       Impact factor: 5.970

6.  Hepatitis C virus E2 envelope glycoprotein core structure.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Rameshwar U Kadam; Kristin E Cogburn; Yuanzi Hua; Xiaoping Dai; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson; Mansun Law
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

Review 7.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

8.  Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Authors:  Rodrigo Velázquez-Moctezuma; Andrea Galli; Mansun Law; Jens Bukh; Jannick Prentoe
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

Review 10.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.